Novartis has reported largely in line Q3 results, driven by a continuation of the recovery momentum in core pharmas while troubles at Sandoz remained. Fortunately, management has announced a strategic review of Sandoz, which in the long term should result in better return metrics and more effective focus on core competencies, i.e. innovative pharmas. While Novartis remains an attractive but under-rated big pharma bet, the near-term sentiment could (continue to) be mired by the recent DoJ investi ....